Egalet Corporation has announced that it has partnered with Septodont, Inc. to promote Sprix ketorolac tromethamine nasal spray to US dentists. Septodont will pay Egalet an undisclosed licensing fee up front, sales-based milestones and a share of profits from net sales.
Sprix was approved by the FDA in 2010 for short-term treatment of moderate-to-severe pain. Its developer, Roxro, was acquired later that year by Daiichi Sankyo subsidiary Luitpold Pharmaceuticals, which launched the product in the US in May 2011.
In January 2015, Egalet announced that it had acquired Sprix from Luitpold, and in December 2015, the company announced that it had partnered with Teva to promote the nasal spray in Israel, Gaza, and the West Bank.
Egalet President and CEO Bob Radie commented, “Through our partnership with Septodont, we are able to broaden our commercial reach bringing Sprix nasal spray to dentists. Given the data published in Postgraduate Medicine that supports the use of Sprix nasal spray as a potent non-opioid option to treat short-term pain following dental procedures, dentists should welcome this effective treatment option for their patients.”
Read the Egalet press release.
